OCTOPUS VENTURES INVESTS £1.5 MILLION IN METRASENS Ltd

Octopus Ventures Ltd (“Octopus”), one of the UK’s leading investment companies in early-stage and expanding companies, has invested £1.5 million into Metrasens Ltd (“Metrasens” or “the Company”), a technology business specialising in metal detection products for the healthcare and security markets.

Metrasens was founded in June 2005 by two former QinetiQ employees. Its core technology was developed within QinetiQ, with whom the business maintains strong links. As a result, it is able to take advantage of over 20 years experience at the forefront of magnetics and metal detection technology.

Investment from Octopus will enable Metrasens to further develop and enhance its already popular Ferroguard® MRI detection system, being used to reduce the likelihood of injuries caused by projectiles in MRI units in both the USA and Europe. The system provides both visual and audible alarms when ferromagnetic material is detected near MRI units. Preventing this type of material from entering MRI rooms can increase safety and decrease potential costs. Funding will also aid sales of its FG1 Portable Security Pole designed for multiple niche applications, such as street knife detection operations by police forces.

The funds were provided by the Octopus Titan VCT 1, Titan VCT 2 and Titan VCT 3 Funds, together with the Octopus Eureka EIS Portfolio Service and the Octopus Investor Group.

With an established global market need for the Company’s Ferroguard® MRI product, early indications suggest that the worldwide market could be worth in excess of £1.1 billion particularly due to tighter regulation of MRI facility design, combined with President Obama’s reforms to reduce the cost of healthcare in the US and the tougher economic environment.

Alex Macpherson, Chief Executive of Octopus Ventures, said: “We were particularly impressed with Metrasens’ strategy for growth in the UK and US markets and are delighted to be working with the Company. With investment from Octopus, we are confident Metrasens is well positioned to significantly enhance its market reach and product range, whilst delivering on customer needs and broadening its customer base.”

Simon Goodyear, CEO, Metrasens, said: “This is an exciting stage in the development of Metrasens, the investment will enable us to implement our ambitious plans for growth. The experience that comes alongside the investment from Octopus will ensure that Metrasens can successfully deliver on the planned expansion in the US medical market and further develop its product lines into the security sector."

Luke Hakes led the deal on behalf of Octopus. Shoosmiths were legal advisers to Octopus.

-ENDS-

Media Enquiries

Octopus Investments Ltd:

Sharon Makin, Media Relations

Tel: +44 (0)20 7710 6470

Email: smakin@octopusinvestments.com

Email: press@octopusinvestments.com

Notes to Editors

About Octopus Investments Ltd (www.octopusinvestments.com)

Established in 2000, Octopus Investments is a leading investment specialist, providing investors with access to a growing range of innovative investment solutions including a discretionary management service, a range of single manager funds; equity OEICS, venture capital trusts, enterprise investment schemes and inheritance tax solutions. Since inception, Octopus has grown its customer base to over 22,000 with funds under management of over £1.4 billion. Octopus was voted ‘VCT Provider of the Year’ in 2007, 2008, 2009 and 2010.

Octopus was voted the top UK financial services company to work for in the Sunday Times survey of ‘Best 100 SMEs to Work For’ in 2008 and was re-listed in the top 100 companies for 2009. Additionally, the Company won the ‘Badenoch & Clark Business of the Year’ award and the ‘3i Growth Strategy of the Year Award’ at the 2008 National Business Awards, Regional Finals, South East of England, in July 2008, and the ‘Business of the Year’ award at the 2009 National Business Awards, Regional Finals, South East of England, in July 2009. Octopus has over 100 staff with 30+ investment professionals.

About Octopus Ventures (www.octopusventures.com)

Octopus Ventures, a division of Octopus Investments, manages circa £250 million in VCT and EIS funds as well as the £30 million Octopus Capital for Enterprise (OCfE) Fund. Octopus typically invests from £500,000 to £5 million per investment and is a leading player in the UK venture capital industry. Octopus is a generalist investor, preferring to back exceptional entrepreneurial teams rather than specific sectors. Octopus looks for businesses which can create, transform or dominate an industry and is focused on the UK. Octopus has £125 million to invest in the next three years.